Galanthamine

Drugs and Aging

Volumn 9, Issue 1, 1996, Pages 60-65

  Fulton, B ^a   Benfield, P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; GALANTAMINE; TACRINE;

ABDOMINAL PAIN; AGITATION; ALZHEIMER DISEASE; BRAIN TISSUE; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DRUG SELECTIVITY; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEARNING; LIVER TOXICITY; MEMORY; MYASTHENIA GRAVIS; NAUSEA; NEUROPSYCHIATRY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARALYSIS; PRIORITY JOURNAL; RATING SCALE; REVIEW; SLEEP DISORDER; VERTIGO; VOMITING;

EID: 0030018834     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609010-00006     Document Type: Review

References (23)

1. 1. J Bonner 1995 Flower bulbs slow brain disease New Sci 145 21 Bonner J. Flower bulbs slow brain disease. New Sci 1995 Feb 11; 145: 21
2. 2. U Bickel T Thomsen JP Fischer 1991 Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice Neuropharmacology 30 447 54 1865992 10.1016/0028-3908(91)90005-V 1:CAS:528:DyaK3MXkvVCkt7w%3D Bickel U, Thomsen T, Fischer JP, et al. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991 May; 30: 447–54
3. 3. T Thomsen H Kewitz 1990 Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo Life Sci 46 1553 8 2355800 10.1016/0024-3205(90)90429-U 1:CAS:528:DyaK3cXktlCmu7g%3D Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46: 1553–8
4. 4. G Pacheco R Palacios-Esquivel DE Moss 1995 Cholinesterase inhibitors proposed for treating dementia in Alzheimer’s disease: selectivity toward human brain acetylcholinesterase compared with butyryleholinesterase J Pharmacol Exp Ther 274 2 767 70 7636741 1:CAS:528:DyaK2MXnsFSjtrc%3D Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer’s disease: selectivity toward human brain acetylcholinesterase compared with butyryleholinesterase. J Pharmacol Exp Ther 1995; 274(2): 767–70
5. 5. T Thomsen B Kaden JP Fischer 1991 Inhibition of acetyleholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine Eur J Clin Chem Clin Biochem 29 487 92 1954303 1:CAS:528:DyaK3MXmt1egtrY%3D Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetyleholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991 Aug; 29: 487–92
6. 6. JE Sweeney PS Puttfarcken JT Coyle 1989 Galanthamine, an acetyleholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice Pharmacol Biochem Behav 34 129 37 2626444 10.1016/0091-3057(89)90364-X 1:CAS:528:DyaK3cXkvVKitQ%3D%3D Sweeney JE, Puttfarcken PS, Coyle JT. Galanthamine, an acetyleholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. Pharmacol Biochem Behav 1989 Sep; 34: 129–37
7. 7. U Bickel T Thomsen W Weber 1991 Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition Clin Pharmacol Ther 50 420 8 1914378 10.1038/clpt.1991.159 1:CAS:528:DyaK3MXmsVyjsrs%3D Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991 Oct; 50: 420–8
8. 8. T Thomsen U Bickel JP Fischer 1990 Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans Eur J Clin Pharmacol 39 603 5 2095347 10.1007/BF00316106 1:CAS:528:DyaK3MXhsFKmurY%3D Thomsen T, Bickel U, Fischer JP, et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990 Dec; 39: 603–5
9. 9. P Chopin M Briley 1992 Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats Psychopharmacology 106 26 30 1738791 10.1007/BF02253584 1:CAS:528:DyaK38XktVSktro%3D Chopin P, Briley M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 1992 Jan; 106:26–30
10. 10. RJ Fishkin ES Ince WA Carlezon Jr 1993 D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats Behav Neural Biol 59 150 7 8476382 10.1016/0163-1047(93)90886-M 1:CAS:528:DyaK3sXks1art70%3D Fishkin RJ, Ince ES, Carlezon WA Jr, et al. D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats. Behav Neural Biol 1993 Mar; 59: 150–7
11. 11. JE Sweeney CF Höhmann TH Moran 1988 A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice Pharmacol Biochem Behav 31 141 7 3252244 10.1016/0091-3057(88)90325-5 1:CAS:528:DyaL1MXltFahug%3D%3D Sweeney JE, Höhmann CF, Moran TH, et al. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 1988 Sep; 31: 141–7
12. 12. JE Sweeney ES Bachman JT Coyle 1990 Effects of different doses of galanthamine, a long-acting acetyleholinesterase inhibitor, on memory in mice Psychopharmacology Berl 102 191 200 2274601 10.1007/BF02245921 1:CAS:528:DyaK3cXls1Ggtrc%3D Sweeney JE, Bachman ES, Coyle JT. Effects of different doses of galanthamine, a long-acting acetyleholinesterase inhibitor, on memory in mice. Psychopharmacology Berl 1990; 102: 191–200
13. 13. D Petit J Montplaisir D Lorrain 1993 THA does not affect sleep or EEG spectral power in Alzheimer’s disease Biol Psychiatry 33 753 4 8353172 10.1016/0006-3223(93)90128-Z 1:CAS:528:DyaK2cXktVE%3D Petit D, Montplaisir J, Lorrain D, et al. THA does not affect sleep or EEG spectral power in Alzheimer’s disease. Biol Psychiatry 1993; 33: 753–4
14. 14. D Riemann H Gann H Dressing 1994 Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep Psychiatry Res 51 253 67 8208872 10.1016/0165-1781(94)90013-2 1:CAS:528:DyaK2cXlsVyru70%3D Riemann D, Gann H, Dressing H, et al. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Res 1994 Mar; 51: 253–67
15. 15. G Holl M Straschill T Thomsen 1992 Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials Electroencephalogr Clin Neurophysiol 82 445 52 1375552 10.1016/0013-4694(92)90050-R 1:CAS:528:DyaK38Xlt1Cgt7g%3D Holl G, Straschill M, Thomsen T, et al. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials. Electroencephalogr Clin Neurophysiol 1992 Jun; 82: 445–52
16. 16. P Westra MJS van-Thiel GA Vermeer 1986 Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients Br J Anaesth 58 1303 7 3778794 10.1093/bja/58.11.1303 1:CAS:528:DyaL2sXislehtA%3D%3D Westra P, van-Thiel MJS, Vermeer GA, et al. Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 1986 Nov; 58: 1303–7
17. 17. D Mihailova I Yamboliev Z Zhivkova 1989 Pharmacokinetics of galanthamine hydrobromide after single subeutaneous and oral dosage in humans Pharmacology 39 50 8 2587617 10.1159/000138571 1:CAS:528:DyaL1MXkslShur0%3D Mihailova D, Yamboliev I, Zhivkova Z, et al. Pharmacokinetics of galanthamine hydrobromide after single subeutaneous and oral dosage in humans. Pharmacology 1989; 39: 50–8
18. 18. AJ Wagstaff D McTavish 1994 Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease Drugs Aging 4 6 510 40 7521234 10.2165/00002512-199404060-00006 1:STN:280:DyaK2czlsFOntw%3D%3D Jun Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994 Jun; 4(6): 510–40
19. 19. P Dal-Bianco J Maly C Wöber 1991 Galanthamine treatment in Alzheimer’s disease J Neural Transm Suppl 33 59 63 1753253 1:STN:280:DyaK38%2Fpt1ShtQ%3D%3D Dal-Bianco P, Maly J, Wöber C, et al. Galanthamine treatment in Alzheimer’s disease. J Neural Transm Suppl 1991; 33: 59–63
20. 20. M Rainer T Mark A Haushofer 1989 Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer’s type Kewitz Thomsen Bickel Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease) Zuckschwerdt Verlag Munich 233 7 Rainer M, Mark T, Haushofer A. Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer’s type. In: Kewitz, Thomsen, Bickel, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Munich: Zuckschwerdt Verlag, 1989: 233–7
21. 21. M Rainer H Mucke P Janoch 1994 Galanthamine treatment in Alzheimer’s disease: the identification of responders Neuropsychopharmacology 215 [abstract no. P-174-12] Rainer M, Mucke H, Janoch P, et al. Galanthamine treatment in Alzheimer’s disease: the identification of responders [abstract no. P-174-12]. Neuropsychopharmacology 1994 May; 10 Suppl. Part 2: 215
22. 22. H Kewitz H Berzewski M Rainer 1994 Galanthamine, a selective nontoxic acetyleholinesterase inhibitor is significantly superior over placebo in the treatment of SDAT Neuropsychopharmacology 130 [abstract no. P-58-147] Kewitz H, Berzewski H, Rainer M, et al. Galanthamine, a selective nontoxic acetyleholinesterase inhibitor is significantly superior over placebo in the treatment of SDAT [abstract no. P-58-147]. Neuropsychopharmacology 1994 May; 10 Suppl. Part 2: 130
23. 23. Kewitz H, Davis B. Preclinical and clinical studies on galanthamine (G) for Alzheimer’s disease treatment [abstract]. In: 3rd International Springfield Symposium on Advances in Alzheimer Therapy. 1994: 39